US20170022172A1 - Process for the synthesis of chlorzoxazone - Google Patents
Process for the synthesis of chlorzoxazone Download PDFInfo
- Publication number
- US20170022172A1 US20170022172A1 US15/214,499 US201615214499A US2017022172A1 US 20170022172 A1 US20170022172 A1 US 20170022172A1 US 201615214499 A US201615214499 A US 201615214499A US 2017022172 A1 US2017022172 A1 US 2017022172A1
- Authority
- US
- United States
- Prior art keywords
- chlorzoxazone
- chloro
- aminophenol
- process according
- ethyl chloroformate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- TZFWDZFKRBELIQ-UHFFFAOYSA-N chlorzoxazone Chemical compound ClC1=CC=C2OC(O)=NC2=C1 TZFWDZFKRBELIQ-UHFFFAOYSA-N 0.000 title claims abstract description 58
- 229960003633 chlorzoxazone Drugs 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 28
- 230000015572 biosynthetic process Effects 0.000 title abstract description 16
- 238000003786 synthesis reaction Methods 0.000 title abstract description 14
- SWFNPENEBHAHEB-UHFFFAOYSA-N 2-amino-4-chlorophenol Chemical compound NC1=CC(Cl)=CC=C1O SWFNPENEBHAHEB-UHFFFAOYSA-N 0.000 claims abstract description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 19
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 24
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical group [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 11
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 9
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- 235000011181 potassium carbonates Nutrition 0.000 claims description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 abstract description 9
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000004202 carbamide Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000010626 work up procedure Methods 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000010933 acylation Effects 0.000 description 3
- 238000005917 acylation reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- NWSIFTLPLKCTSX-UHFFFAOYSA-N 4-chloro-2-nitrophenol Chemical compound OC1=CC=C(Cl)C=C1[N+]([O-])=O NWSIFTLPLKCTSX-UHFFFAOYSA-N 0.000 description 2
- NNHMQZBVJPQCAK-UHFFFAOYSA-N 5-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC(Cl)=CC=C1O NNHMQZBVJPQCAK-UHFFFAOYSA-N 0.000 description 2
- FTUXZTRMVNKCFO-UHFFFAOYSA-M CC.NC(=O)C1=C(O)C=CC(Cl)=C1.O=C1CC2=CC(Cl)=CC=C2O1.O[Na] Chemical compound CC.NC(=O)C1=C(O)C=CC(Cl)=C1.O=C1CC2=CC(Cl)=CC=C2O1.O[Na] FTUXZTRMVNKCFO-UHFFFAOYSA-M 0.000 description 2
- VCRXAGPBEGKTSI-UHFFFAOYSA-N CCOC(=O)Cl.NC1=C(O)C=CC(Cl)=C1.O=C1CC2=CC(Cl)=CC=C2O1 Chemical compound CCOC(=O)Cl.NC1=C(O)C=CC(Cl)=C1.O=C1CC2=CC(Cl)=CC=C2O1 VCRXAGPBEGKTSI-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- IKCJCELDJAMESE-UHFFFAOYSA-N NC1=C(O)C=CC(Cl)=C1.O=C(Cl)Cl.O=C1CC2=CC(Cl)=CC=C2O1 Chemical compound NC1=C(O)C=CC(Cl)=C1.O=C(Cl)Cl.O=C1CC2=CC(Cl)=CC=C2O1 IKCJCELDJAMESE-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 231100001261 hazardous Toxicity 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 229910052500 inorganic mineral Chemical class 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Chemical class 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000002828 nitro derivatives Chemical class 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000001308 synthesis method Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- XNYTZADDSVJMRC-UHFFFAOYSA-N (5-chloro-2-hydroxyphenyl)urea Chemical compound NC(=O)NC1=CC(Cl)=CC=C1O XNYTZADDSVJMRC-UHFFFAOYSA-N 0.000 description 1
- 0 *C.*C.CC1=CC=CC=C1N.O=C1CC2=CC=CC=C2C1 Chemical compound *C.*C.CC1=CC=CC=C1N.O=C1CC2=CC=CC=C2C1 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical class NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 229910019093 NaOCl Inorganic materials 0.000 description 1
- PSVXTJFRMXQUCP-UHFFFAOYSA-N O=C1CC2=CC(Cl)=CC=C2O1 Chemical compound O=C1CC2=CC(Cl)=CC=C2O1 PSVXTJFRMXQUCP-UHFFFAOYSA-N 0.000 description 1
- WPSCCGVALWBTIA-UHFFFAOYSA-N O=C1CC2=CC(Cl)=CC=C2O1.O=[N+]([O-])C1=C(O)C=CC(Cl)=C1 Chemical compound O=C1CC2=CC(Cl)=CC=C2O1.O=[N+]([O-])C1=C(O)C=CC(Cl)=C1 WPSCCGVALWBTIA-UHFFFAOYSA-N 0.000 description 1
- RTWZLTSEFJJKOS-UHFFFAOYSA-N O=C1CC2=CC(Cl)=CC=C2O1.O=[N+]([O-])C1=C(O)C=CC(Cl)=C1.[Mo][Pd] Chemical compound O=C1CC2=CC(Cl)=CC=C2O1.O=[N+]([O-])C1=C(O)C=CC(Cl)=C1.[Mo][Pd] RTWZLTSEFJJKOS-UHFFFAOYSA-N 0.000 description 1
- 229910021604 Rhodium(III) chloride Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- YGCODSQDUUUKIV-UHFFFAOYSA-N Zoxazolamine Chemical compound ClC1=CC=C2OC(N)=NC2=C1 YGCODSQDUUUKIV-UHFFFAOYSA-N 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 150000004703 alkoxides Chemical class 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000005365 aminothiol group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910044991 metal oxide Inorganic materials 0.000 description 1
- 150000004706 metal oxides Chemical class 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- SONJTKJMTWTJCT-UHFFFAOYSA-K rhodium(iii) chloride Chemical compound [Cl-].[Cl-].[Cl-].[Rh+3] SONJTKJMTWTJCT-UHFFFAOYSA-K 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- 238000001946 ultra-performance liquid chromatography-mass spectrometry Methods 0.000 description 1
- 150000003681 vanadium Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
Definitions
- Chlorzoxazone 5-chlorobenzo[d]oxazol-2(3H)-one, is a muscle relaxant which acts at central level and is used in the treatment of muscle spasms and the resulting pain. Chlorzoxazone acts on the spinal cord, by depressing/suppressing the reflexes.
- chlorzoxazone (1) is synthesised by loading concentrated HCl, 4-chloro-2-aminophenol and urea into an autoclave and heating them in an inert atmosphere at 125° C. After cooling to room temperature, the crystalline paste that precipitates is suspended in 1500 parts of water, the pH of the suspension is adjusted to 5-6, and the paste is heated at 100° C. for an hour. After cooling, the residue is filtered and washed under vacuum to obtain chlorzoxazone (1) with a yield of 91%.
- CN1560040 and CN103360336 also report the synthesis of chlorzoxazone (1) by reacting 4-chloro-2-aminophenol with urea at high temperatures in the presence of mineral acids (HCl or H 2 SO 4 ).
- CN1560040 also discloses the synthesis of chlorzoxazone using phosgene
- Another synthesis method involves cyclisation of 5-chloro-salicylamide by the action of 13% NaOH.
- JP4834875 An alternative synthesis method not requiring the use of urea or phosgene is described in JP4834875, wherein a mixture of 4-chloro-2-nitrophenol, benzene, RhCl 3 and V 2 O 5 is heated in an autoclave with CO.
- chlorzoxazone (1) is obtained by heating a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
- a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
- a base e.g. triethylamine
- SK278412 describes a process wherein 4-chloro-2-nitrophenol is carbonylated with CO at high temperatures in the presence of catalytic systems such as S, COS, H 2 S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V 2 O 5 , V 2 S 5 , NH 3 VO 3 ).
- catalytic systems such as S, COS, H 2 S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V 2 O 5 , V 2 S 5 , NH 3 VO 3 ).
- EP0087347 discloses (Example 7) the synthesis of chlorzoxazone (1) obtained directly from the nitro derivative in the presence of pyridine and of a catalyst based on palladium and molybdenum in a CO atmosphere (200 bars) at 200° C. Cyclic carbamate is then isolated by cooling, filtration of the catalyst and recrystallisation of the product from water.
- RO75779 discloses the synthesis of chlorzoxazone (1) from 5-Cl-salicylamide; in particular, the desired product is obtained by treating the amide in water, NaOH and butanol with 13% NaOCl at 35° C.
- the process takes place by degrees, without isolation of intermediate reaction products.
- the process therefore comprises:
- the process of the invention typically involves the synthesis of chlorzoxazone (1) by acylation of 4-chloro-2-aminophenol with ethyl chloroformate in an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
- an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
- Chlorzoxazone (1) obtained is isolated directly from the reaction mixture by simple filtration. The quality of the synthesised product exceeds 98%.
- the process is performed as follows:
- 1 mole of 4-chloro-2-aminophenol is reacted with 0.9-1.5 moles of ethyl chloroformate, preferably 1.2-1.4 moles, in the presence of an inorganic base, preferably potassium carbonate, in quantities ranging from 1.0 to 4.0 moles, preferably from 2.0 to 3.0 mole equivalents.
- the reaction is performed in organic solvent or mixtures of solvents selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate or in water, preferably in ethyl acetate, acetonitrile, N,N-dimethylformamide and water, in the temperature range between 0° C.
- reaction temperature addition temperature
- 80° C. or reflux temperature in the case of low-boiling solvents, preferably at the temperature of 55-60° C. 4-15 volumes of solvent are used, preferably 5-7 volumes relative to the quantity of 4-chloro-2-aminophenol.
- the reaction is monitored by UPLC analysis using an ACQUITY UPLC® BEH C18 column, 17 ⁇ m, 2.1 ⁇ 50 mm, and water/acetonitrile/0.1% formic acid as eluent phase.
- the reaction mixture containing chlorzoxazone (1) is cooled to the temperature of 0-25° C., preferably 0-10° C., and filtered.
- the solid is re-washed with water and dried under vacuum at the temperature of 30-90° C., preferably 60-70° C., to obtain chlorzoxazone with a purity exceeding 98%.
- the resulting solid can be further purified if necessary by recrystallisation from ethyl acetate, ethanol or other known solvents.
- the process of the invention is particularly advantageous in that ethyl chloroformate is cheap and readily available, is not classified as a toxic gas, unlike phosgene and CO, does not need strict anhydrous conditions, which means that the reaction can take place in water, and does not need high reaction temperatures as with the use of urea.
- chlorzoxazone (1) is obtained directly from the reaction mixture by simple filtration of the suspension at the end of the reaction with very high yields and quality, thus considerably simplifying the work-up stages described in the literature.
- Ethyl chloroformate (9.8 g, 90.5 mmol) is dripped into a suspension of potassium carbonate (27.9 g, 201.8 mol) and 4-chloro-2-aminophenol (10.0 g, 69.6 mmol) in ethyl acetate (70 mL), heated to 60° C., in 4 hours. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with ethyl acetate (15 mL).
- Ethyl chloroformate (2.9 g, 26.3 mmol) is dripped into a solution of 4-chloro-2-aminophenol (3.0 g, 20.9 mmol) and triethylamine (2.7 g, 26.3 mmol) in acetonitrile (20.9 mL), cooled to 0° C. The mixture is left under stirring at 0° C. for one hour, and potassium carbonate (8.4 g, 60.8 mmol) is then added. The resulting mixture is left under stirring at 60° C. for 18 h. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with acetonitrile (5 mL).
- Ethyl chloroformate (1.96 g, 18.1 mmol) is dripped into a suspension of sodium bicarbonate (5.8 g, 69.0 mmol) and 4-chloro-2-aminophenol (2.0 g, 13.9 mmol) in water (11 ml) at 0° C.
- the mixture is left to stand at room temperature for about half an hour, after which potassium carbonate is added and the reaction mixture is heated to 55-60° C.
- the reaction is finished after 2 hours.
- the reaction mixture is filtered and re-washed with water (10 mL) to obtain chlorzoxazone (1) (2.3 g, 13.6 mol) with a purity exceeding 95%.
- Molar yield from 4-chloro-2-aminophenol to chlorzoxazone 98%.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
- This application claims priority to and the benefit of Italian Patent Application No. 102015000037594 filed on Jul. 23, 2015, incorporated herein by reference in its entirety.
- Chlorzoxazone, 5-chlorobenzo[d]oxazol-2(3H)-one, is a muscle relaxant which acts at central level and is used in the treatment of muscle spasms and the resulting pain. Chlorzoxazone acts on the spinal cord, by depressing/suppressing the reflexes.
- A number of examples of synthesis of chlorzoxazone (1) from 4-chloro-2-aminophenol, into which an acyl group, usually from urea or phosgene, is inserted, are described in the literature. Cases in which the carbonyl group inserted is directly gaseous CO are also reported.
- A representative example of the use of urea for the synthesis of chlorzoxazone (1) is reported in U.S. Pat. No. 3,812,138 (DE2131366), which discloses the formation of dibenzothiazolones from various aminophenols/aminothiols in the presence of urea and mineral acids according to the following synthesis scheme:
- Specifically, chlorzoxazone (1) is synthesised by loading concentrated HCl, 4-chloro-2-aminophenol and urea into an autoclave and heating them in an inert atmosphere at 125° C. After cooling to room temperature, the crystalline paste that precipitates is suspended in 1500 parts of water, the pH of the suspension is adjusted to 5-6, and the paste is heated at 100° C. for an hour. After cooling, the residue is filtered and washed under vacuum to obtain chlorzoxazone (1) with a yield of 91%.
- The patent does not report the degree of purity of the product obtained and, despite the high yield of the process, this synthesis is not particularly economical in terms of energy because very high temperatures are used. Moreover, the required work-up considerably increases the volumes of work, making it inefficient on an industrial scale.
- CN1560040 and CN103360336 also report the synthesis of chlorzoxazone (1) by reacting 4-chloro-2-aminophenol with urea at high temperatures in the presence of mineral acids (HCl or H2SO4).
- CN1560040 also discloses the synthesis of chlorzoxazone using phosgene
- The same document also describes the synthesis of chlorzoxazone (1) from the nitro derivative by reacting it with gaseous CO, which leads to the formation of cyclic carbamate
- Another synthesis method involves cyclisation of 5-chloro-salicylamide by the action of 13% NaOH.
- An alternative process using phosgene is reported in U.S. Pat. No. 3,369,022. The cyclisation of 4-chloro-2-aminophenol is described in procedure no. 2, according to the following synthesis scheme:
- In particular, a solution of phosgene in ethyl acetate is dripped into a suspension of 4-chloro-2-aminophenol and sodium acetate in ethyl acetate. The reaction mixture is heated to reflux and cooled, then washed with water containing 5% hydrochloric acid. After a distillation under vacuum and a further crystallisation, the product is obtained.
- The procedure does not provide any data relating to the yield or purity of the chlorzoxazone (1) obtained, but even if they were excellent, the process presents the significant drawback of the manageability of phosgene, a particularly reactive, toxic reagent which requires special precautions for both use and disposal.
- Another example of synthesis of chlorzoxazone (1) involving the use of phosgene is reported in EP0477819. The procedure described therein also appears unsatisfactory in terms of yields.
- Alternative methods of synthesising chlorzoxazone are described in U.S. Pat. No. 2,895,877. Starting with 2-amino-5-chlorobenzoxazole or N-(5-chloro-2-hydroxyphenyl)urea at reflux in 1N HCl a solid precipitates which, after a basic work-up and an acid work-up, is crystallised from a suitable solvent.
- An alternative synthesis method not requiring the use of urea or phosgene is described in JP4834875, wherein a mixture of 4-chloro-2-nitrophenol, benzene, RhCl3 and V2O5 is heated in an autoclave with CO.
- Also in JP58225072, chlorzoxazone (1) is obtained by heating a suitable nitrophenol with CO in hydrated organic solvent (e.g. THF) in the presence of a base (e.g. triethylamine) and selenium.
- SK278412 describes a process wherein 4-chloro-2-nitrophenol is carbonylated with CO at high temperatures in the presence of catalytic systems such as S, COS, H2S or CS, bases (alkoxides, alkaline metal oxides, etc.) and vanadium derivatives (V2O5, V2S5, NH3VO3).
- EP0087347 discloses (Example 7) the synthesis of chlorzoxazone (1) obtained directly from the nitro derivative in the presence of pyridine and of a catalyst based on palladium and molybdenum in a CO atmosphere (200 bars) at 200° C. Cyclic carbamate is then isolated by cooling, filtration of the catalyst and recrystallisation of the product from water.
- The use of CO is problematic; said gas is highly poisonous, and insidious because it is odourless, colourless and tasteless. Its extremely hazardous nature requires particular precautions which make its industrial use extremely complicated.
- RO75779 discloses the synthesis of chlorzoxazone (1) from 5-Cl-salicylamide; in particular, the desired product is obtained by treating the amide in water, NaOH and butanol with 13% NaOCl at 35° C.
- On the basis of the information set out above, there is clearly a need to find a process for synthesising chlorzoxazone (1) that is easier to manage industrially, safer, by avoiding the use of reagents which are extremely hazardous to humans and the environment, and more economical.
- An advantageous process for the preparation of chlorzoxazone (1) has been found wherein 4-chloro-2-aminophenol is surprisingly closed with cyclic urethane due to ethyl chloroformate in the presence of a base, according to the following scheme:
- The process takes place by degrees, without isolation of intermediate reaction products.
- The process therefore comprises:
- 1) acylation of 4-chloro-2-aminophenol (cyclisation of the various acylation products);
- 2) isolation of chlorzoxazone (1) from the reaction mixture by simple filtration of the reaction solvent.
- The process of the invention typically involves the synthesis of chlorzoxazone (1) by acylation of 4-chloro-2-aminophenol with ethyl chloroformate in an organic solvent selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate, or in water in the presence of an inorganic base, preferably potassium carbonate, potassium bicarbonate, sodium carbonate or sodium bicarbonate.
- The order in which the various solvents, raw materials and base are added can differ from that reported below.
- Chlorzoxazone (1) obtained is isolated directly from the reaction mixture by simple filtration. The quality of the synthesised product exceeds 98%.
- According to a preferred embodiment of the invention, the process is performed as follows:
- 1 mole of 4-chloro-2-aminophenol is reacted with 0.9-1.5 moles of ethyl chloroformate, preferably 1.2-1.4 moles, in the presence of an inorganic base, preferably potassium carbonate, in quantities ranging from 1.0 to 4.0 moles, preferably from 2.0 to 3.0 mole equivalents. The reaction is performed in organic solvent or mixtures of solvents selected from acetonitrile, N,N-dimethylformamide, dichloromethane, toluene, acetone and ethyl acetate or in water, preferably in ethyl acetate, acetonitrile, N,N-dimethylformamide and water, in the temperature range between 0° C. (addition temperature) and 80° C. or reflux temperature in the case of low-boiling solvents, preferably at the temperature of 55-60° C. 4-15 volumes of solvent are used, preferably 5-7 volumes relative to the quantity of 4-chloro-2-aminophenol. The reaction is monitored by UPLC analysis using an ACQUITY UPLC® BEH C18 column, 17 μm, 2.1×50 mm, and water/acetonitrile/0.1% formic acid as eluent phase. After completion of the reaction, the reaction mixture containing chlorzoxazone (1) is cooled to the temperature of 0-25° C., preferably 0-10° C., and filtered. The solid is re-washed with water and dried under vacuum at the temperature of 30-90° C., preferably 60-70° C., to obtain chlorzoxazone with a purity exceeding 98%. The resulting solid can be further purified if necessary by recrystallisation from ethyl acetate, ethanol or other known solvents.
- The process of the invention is particularly advantageous in that ethyl chloroformate is cheap and readily available, is not classified as a toxic gas, unlike phosgene and CO, does not need strict anhydrous conditions, which means that the reaction can take place in water, and does not need high reaction temperatures as with the use of urea.
- Moreover, chlorzoxazone (1) is obtained directly from the reaction mixture by simple filtration of the suspension at the end of the reaction with very high yields and quality, thus considerably simplifying the work-up stages described in the literature.
- The invention is illustrated in detail in the following examples.
- Ethyl chloroformate (9.8 g, 90.5 mmol) is dripped into a suspension of potassium carbonate (27.9 g, 201.8 mol) and 4-chloro-2-aminophenol (10.0 g, 69.6 mmol) in ethyl acetate (70 mL), heated to 60° C., in 4 hours. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with ethyl acetate (15 mL). The crude product is reduced to a pulp in water for 1.5 hours, filtered under vacuum and washed with water (10 mL); chlorzoxazone (1) (11.1 g), with a purity exceeding 98%, is obtained. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 94%.
- Ethyl chloroformate (2.9 g, 26.3 mmol) is dripped into a solution of 4-chloro-2-aminophenol (3.0 g, 20.9 mmol) and triethylamine (2.7 g, 26.3 mmol) in acetonitrile (20.9 mL), cooled to 0° C. The mixture is left under stirring at 0° C. for one hour, and potassium carbonate (8.4 g, 60.8 mmol) is then added. The resulting mixture is left under stirring at 60° C. for 18 h. After completion of the reaction, the mixture is cooled at 5° C. for 1.5 hours, and the reaction mixture is filtered and re-washed with acetonitrile (5 mL). The crude product is reduced to a pulp in water for 1.5 hours, filtered under vacuum and washed with water (10 mL); chlorzoxazone (1), with a purity exceeding 96%, is obtained. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 92%.
- Ethyl chloroformate (1.96 g, 18.1 mmol) is dripped into a suspension of sodium bicarbonate (5.8 g, 69.0 mmol) and 4-chloro-2-aminophenol (2.0 g, 13.9 mmol) in water (11 ml) at 0° C. The mixture is left to stand at room temperature for about half an hour, after which potassium carbonate is added and the reaction mixture is heated to 55-60° C. The reaction is finished after 2 hours. The reaction mixture is filtered and re-washed with water (10 mL) to obtain chlorzoxazone (1) (2.3 g, 13.6 mol) with a purity exceeding 95%. Molar yield from 4-chloro-2-aminophenol to chlorzoxazone: 98%.
- UPLC-MS [M-H]−=168 m/z
- 1H-NMR (in DMSO) (chemical shifts expressed in ppm relative to the TMS signal): 11.82 (1H, s), 7.31 (1H, d), 7.15 (1H, dd), 7.13-7.11 (1H, m). 13C-NMR: 154.7, 142.6, 132.2, 128.2, 121.9, 111.2, 110.3.
Claims (9)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITUB2015A002422A ITUB20152422A1 (en) | 2015-07-23 | 2015-07-23 | PROCESS FOR CHLORZOXAZONE SYNTHESIS |
| IT102015000037594 | 2015-07-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20170022172A1 true US20170022172A1 (en) | 2017-01-26 |
| US9567308B1 US9567308B1 (en) | 2017-02-14 |
Family
ID=54364513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US15/214,499 Expired - Fee Related US9567308B1 (en) | 2015-07-23 | 2016-07-20 | Process for the synthesis of chlorzoxazone |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US9567308B1 (en) |
| IT (1) | ITUB20152422A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113816920A (en) * | 2020-06-18 | 2021-12-21 | 鲁南制药集团股份有限公司 | Synthetic method of chlorzoxazone |
| CN117285480A (en) * | 2023-09-21 | 2023-12-26 | 河南康达制药有限公司 | Method and device for preparing chlorzoxazone |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2895877A (en) * | 1956-07-30 | 1959-07-21 | Mcneilab Inc | Composition and method for relieving spasticity |
| BR7204020D0 (en) * | 1971-06-24 | 1973-11-01 | Hoechst Ag | PROCESS FOR OBTAINING BENZOXAZOLONES- (2) AND BENZOTIAZOLONES- (2) |
| FR2521994A1 (en) * | 1982-02-23 | 1983-08-26 | Ugine Kuhlmann | PROCESS FOR THE PREPARATION OF BENZOXAZOLONE-2 AND DERIVATIVES FROM ORTHONITROPHENOLS AND CARBON MONOXIDE |
-
2015
- 2015-07-23 IT ITUB2015A002422A patent/ITUB20152422A1/en unknown
-
2016
- 2016-07-20 US US15/214,499 patent/US9567308B1/en not_active Expired - Fee Related
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113816920A (en) * | 2020-06-18 | 2021-12-21 | 鲁南制药集团股份有限公司 | Synthetic method of chlorzoxazone |
| CN117285480A (en) * | 2023-09-21 | 2023-12-26 | 河南康达制药有限公司 | Method and device for preparing chlorzoxazone |
Also Published As
| Publication number | Publication date |
|---|---|
| US9567308B1 (en) | 2017-02-14 |
| ITUB20152422A1 (en) | 2017-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3271018B1 (en) | Processes and intermediates for the preparation of pimavanserin | |
| HUE029528T2 (en) | A process for the preparation of 6-(7-((1-aminocyclopropyl)methoxy)-6-methoxyquinolin-4-yloxy)-N-methyl-1-naphthamide and synthetic intermediates thereof | |
| US9567308B1 (en) | Process for the synthesis of chlorzoxazone | |
| CS259887B2 (en) | Method of 2-amino-3-nitro-6(fluorobenzylamino)pyridine production | |
| KR0178542B1 (en) | Salts of dithiocarbamic acid, a method for producing the same, and a method for producing isothiocyanates using the salts of the dithiocarbamic acid | |
| NO317648B1 (en) | Process for Preparation of HIV Protease Inhibitors | |
| US6559291B1 (en) | Process for the preparation of diazonaphthoquinonesulfonylchlorides using diphosgene and triphosgene | |
| CN113242856A (en) | N-nitrosaccharin | |
| EP1348693B1 (en) | A process for the preparation of diazonaphthoquinonesulfonylchlorides using diphosgene and triphosgene | |
| CN109265455B (en) | Preparation method of dasatinib | |
| US5321151A (en) | Process for preparation of iodopropargyl carbamates | |
| JP2818476B2 (en) | Method for producing chlorinated nicotinaldehyde | |
| JP4639382B2 (en) | Novel N-sulfenylbenzotriazole compound and method for producing the same | |
| Takechi et al. | Synthesis of 3-aminoflavones from 3-hydroxyflavones via 3-tosyloxy-or 3-mesyloxyflavones | |
| EP0413832A1 (en) | Oxazolidinedione derivatives and production thereof | |
| US20090286996A1 (en) | Process for the preparation of zileuton | |
| RU2754708C1 (en) | Method for obtaining gliclazide | |
| CZ2011491A3 (en) | Process for preparing chlorocarbonates | |
| US7288678B2 (en) | Process for preparing terbinafine by using platinum as catalyst | |
| RU2315747C2 (en) | Method for production of acetylene compound | |
| EP3710445B1 (en) | Process for the preparation of raltegravir | |
| EP0200429A2 (en) | Process for preparing methylcarbamate insecticides | |
| US4603211A (en) | Process for the preparation of 1,2-benzoxathiine derivatives | |
| WO2019008595A1 (en) | Process for the preparation of 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1- methylpiperidin-4-yl)urea and salts thereof | |
| EP1832578B1 (en) | Method for producing thiocarbamate derivative |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: PROCOS S.P.A., ITALY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BOGOGNA, LUIGI;CICIONE, LAVINIA;BAROZZA, ALESSANDRO;AND OTHERS;REEL/FRAME:039195/0159 Effective date: 20160526 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20210214 |